Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
Open Access
- 9 January 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (2)
Abstract
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response remain unclear. Our investigation into the effects of anti-CTLA-4 and anti-PD-1 on memory T cell formation in mice reveals that memory T cells generated by anti-CTLA-4 exhibit greater expansion, cytokine production, and antitumor activity than those from anti-PD-1. Notably, anti-CTLA-4 preserves more T cell factor-1 (TCF-1)+ T cells during priming, while anti-PD-1 leads to more thymocyte selection-associated high mobility group box (TOX)+ T cells. Experiments using conditional Tcf7 - or Tox -knockout mice highlight that TCF-1 is essential for the memory response generated by anti-CTLA-4, whereas TOX deletion alone in T cells has no effect on the response to anti-PD-1. Deepening our understanding of how checkpoint inhibition affects memory response is crucial for advancing our understanding of the enduring impacts of these immunotherapies on the immune system.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (R1203)
- HHS | NIH (AI155577 AI115712 AI117950 AI108545 AI082630)
This publication has 39 references indexed in Scilit:
- Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapyCancer Cell, 2023
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control MechanismsImmunity, 2020
- TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate DecisionImmunity, 2019
- Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T CellsImmunity, 2018
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)The Lancet, 2017
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral InfectionsImmunity, 2016
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaJAMA, 2016
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisCancer Cell, 2015
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994